Autolus Therapeutics' obe-cel, branded Aucatzyl, is the first CAR-T therapy approved without a REMS, highlighting its safety and unique mechanism.

The international consulting firm Clarivate makes its bet among the novelties ready for the medicine cabinet this year: three ...

Priya Hays, Hays Documentation Specialists, discusses innovations and advancements in the development of personalized cancer ...

Wong, Founder and CEO of HCW Biologics, commented, “The FDA’s clearance to initiate our first-in-human clinical trial for HCW9302 brings us one step closer to advancing a potentially transformative ...

A group of 18 colorectal cancer patients experienced complete remission after taking the experimental drug dostarlimab for ...

Collaboration to explore the immunoregulation of NK and T cells within the tumor microenvironment (TME) by CAPTN-3, with the goal of enhancing ...

The total consideration to acquire 100 percent of the issued share capital by Biotheus amounts to $800 million, predominantly in cash, with a small portion in BioNTech American Depositary Shares, plus ...

Findings indicate that altering glucose metabolism in T cells boosts their therapeutic potential against melanoma, paving the way for improved immunotherapies.

With every bite of food we take, our intestinal immune system must make a big decision. Tasked with defending us from foreign ...

In addition to new treatments over the past few years changing the landscape for patients, additional treatments being evaluated are looking at new mechanisms ... receptor T-cell therapy vs ...

Our dataset also suggests activated survival mechanisms in T cells, allowing them to bypass apoptotic and senescent cues, and explains telomere lengthening during spaceflight. Additionally, we uncover ...